Although emerging biologic medicines (e.g., TNF inhibitors) have been employed in recent years to treat patients with RA with an inadequate response to DMARDs (22–25), studies have shown that their usage is linked with an increased risk of infection in patients with RA (26–28). This evidence concerns the gene TNF and rheumatoid arthritis.